<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2017.7506</article-id>
<article-id pub-id-type="publisher-id">mmr-16-05-7617</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Investigation of crucial genes and microRNAs in conventional osteosarcoma using gene expression profiling analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Peng</surname><given-names>Chuangang</given-names></name>
<xref rid="af1-mmr-16-05-7617" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Qi</given-names></name>
<xref rid="af2-mmr-16-05-7617" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Wei</surname><given-names>Bo</given-names></name>
<xref rid="af3-mmr-16-05-7617" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Baoming</given-names></name>
<xref rid="af1-mmr-16-05-7617" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yong</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Yuxiang</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Gu</surname><given-names>Dawer</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Yin</surname><given-names>Guochao</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Bo</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Xu</surname><given-names>Dehui</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xuebing</given-names></name>
<xref rid="af4-mmr-16-05-7617" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Kong</surname><given-names>Daliang</given-names></name>
<xref rid="af5-mmr-16-05-7617" ref-type="aff">5</xref>
<xref rid="c1-mmr-16-05-7617" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-16-05-7617"><label>1</label>Orthopaedic Medical Center, The 2nd Hospital of Jilin University, Changchun, Jilin 130041, P.R. China</aff>
<aff id="af2-mmr-16-05-7617"><label>2</label>Department of Gynecology and Obstetrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff>
<aff id="af3-mmr-16-05-7617"><label>3</label>Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff>
<aff id="af4-mmr-16-05-7617"><label>4</label>Department of Orthopaedics, Jilin Oilfield General Hospital, Songyuan, Jilin 131200, P.R. China</aff>
<aff id="af5-mmr-16-05-7617"><label>5</label>Department of Orthopaedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-16-05-7617"><italic>Correspondence to</italic>: Dr Daliang Kong, Department of Orthopaedics, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin 130033, P.R. China, E-mail: <email>kdaliang@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>05</month><year>2017</year></pub-date>
<pub-date pub-type="epub"><day>18</day><month>09</month><year>2017</year></pub-date>
<volume>16</volume>
<issue>5</issue>
<fpage>7617</fpage>
<lpage>7624</lpage>
<history>
<date date-type="received"><day>23</day><month>11</month><year>2016</year></date>
<date date-type="accepted"><day>03</day><month>07</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017, Spandidos Publications</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<abstract>
<p>The present study aimed to screen potential genes associated with conventional osteosarcoma (OS) and obtain further information on the pathogenesis of this disease. The microarray dataset GSE14359 was downloaded from the Gene Expression Omnibus. A total of 10 conventional OS samples and two non-neoplastic primary osteoblast samples in the dataset were selected to identify the differentially expressed genes (DEGs) using the Linear Models for Microarray Data package. The potential functions of the DEGs were predicted using Gene Ontology (GO) and pathway enrichment analyses. Protein-protein interaction (PPI) data were also obtained using the Search Tool for the Retrieval of Interacting Genes database, and the PPI network was visualized using Cytoscape. Module analysis was then performed using the Molecular Complex Detection module. Additionally, the potential microRNAs (miRNAs) for the upregulated DEGs in the most significant pathway were predicted using the miRDB database, and the regulatory network for the miRNAs-DEGs was visualized in Cytoscape. In total, 317 upregulated and 670 downregulated DEGs were screened. Certain DEGs, including cyclin-dependent kinase 1 (<italic>CDK1</italic>), mitotic arrest deficient 2 like 1 (<italic>MAD2L1</italic>) and BUB1 mitotic checkpoint serine/threonine-protein kinase (<italic>BUB1</italic>), were significantly enriched in the cell cycle phase and oocyte meiosis pathway. DEGs, including replication factor C subunit 2 (<italic>RFC2</italic>), <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic>, were significantly enriched in DNA replication and interacted with each other. <italic>RFC4</italic> also interacted with other DEGs, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, NDC80 kinetochore complex and <italic>BUB1</italic>. In addition, <italic>RFC4</italic>, <italic>RFC3</italic> and <italic>RFC5</italic> were targeted by miRNA (miR)-802, miR-224-3p and miR-522-3p. The DEGs encoding RFC may be important for the development of conventional OS, and their expression may be regulated by a number of miRNAs, including miR-802, miR-224-3p and miR-522-3p.</p>
</abstract>
<kwd-group>
<kwd>conventional osteosarcoma</kwd>
<kwd>differentially expressed genes</kwd>
<kwd>microRNA</kwd>
<kwd>protein-protein interaction</kwd>
<kwd>network</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Osteosarcoma (OS) is the most common malignancy of bone in early adolescence (<xref rid="b1-mmr-16-05-7617" ref-type="bibr">1</xref>). Conventional OS, also termed classical OS, is a common type of OS and is universally life-threatening due to its rapid growth, high local aggression and metastatic potential (<xref rid="b2-mmr-16-05-7617" ref-type="bibr">2</xref>). During previous years, considerable progress has been made in identifying the key components in conventional OS, including genes, pathways and microRNAs (miRNAs). For example, during osteoblast differentiation, miRNA (miR)-34 is significantly induced by bone morphogenetic protein 2, and regulates multiple components of the Notch signalling pathway, including Notch1, Notch2 and jagged 1, which affects osteoclast differentiation. This regulatory association may be closely associated with the pathogenesis of OS (<xref rid="b3-mmr-16-05-7617" ref-type="bibr">3</xref>). In addition, phosphatase and tensin homolog (PTEN) has been found to be a potent regulator of the phosphatidylinositol 3-kinase (PI3K) /serine-threonine kinase (Akt) pathway (<xref rid="b4-mmr-16-05-7617" ref-type="bibr">4</xref>), and the loss of <italic>PTEN</italic> is a common occurrence in conventional OS (<xref rid="b5-mmr-16-05-7617" ref-type="bibr">5</xref>). A previous study has showed that the expression of <italic>PTEN</italic> can be inhibited by miR-221, which potentiates the PI3K/Akt pathway in the conventional pathogenesis of OS (<xref rid="b6-mmr-16-05-7617" ref-type="bibr">6</xref>). <italic>PTEN</italic> is also a target of miR-92a, and of members of the miR-17 and miR-130/301 families in OS (<xref rid="b7-mmr-16-05-7617" ref-type="bibr">7</xref>).</p>
<p>In 2010, using genome-wide microarrays, Fritsche-Guenther <italic>et al</italic> (<xref rid="b8-mmr-16-05-7617" ref-type="bibr">8</xref>) found that the aberrant expression of ephrin receptor A2 (EphA2) and its ligand, EFNA1 in OS can modulate the activation of the mitogen-activated protein kinase (MAPK) pathway. In addition, it was found that the expression of CD52 was higher in OS metastases compared with conventional OS metastases, and CAMPATH-1H, an antibody directed against CD52, reduced the number of viable OS cells (<xref rid="b9-mmr-16-05-7617" ref-type="bibr">9</xref>). In 2013, Luo <italic>et al</italic> (<xref rid="b10-mmr-16-05-7617" ref-type="bibr">10</xref>) found numerous differentially expressed genes (DEGs) and regulatory associations between transcription factors and DEGs in OS using the microarray data deposited by Fritsche-Guenther <italic>et al</italic> For example, interleukin 6 can be regulated by tumour protein p53 (<italic>TP53</italic>), nuclear factor I/C (CCAAT-binding transcription factor), retinoic acid receptor &#x03B1;, and CCAAT/enhancer binding protein &#x03B2;. In 2014, Yang <italic>et al</italic> (<xref rid="b11-mmr-16-05-7617" ref-type="bibr">11</xref>) also identified a number of DEGs, Gene Ontology (GO) terms, including protein binding, and significant pathways, including focal adhesion, in OS based on a meta-analysis of eight expression profiles, including the one deposited by Fritsche-Guenther (<xref rid="b8-mmr-16-05-7617" ref-type="bibr">8</xref>). However, in these previous studies, the potential miRNAs and regulatory associations between miRNAs and DEGs in OS were not examined.</p>
<p>In the present study, to screen and identify additional DEGs and miRNAs in conventional OS, the microarray data deposited by Fritsche-Guenther (<xref rid="b8-mmr-16-05-7617" ref-type="bibr">8</xref>) were downloaded. Following GO and pathway enrichment analyses, and construction of a protein-protein interaction (PPI) network for the DEGs, the potential miRNAs in the most significant pathway for the upregulated DEGs were identified, and a regulatory network for the miRNAs-DEGs was constructed. The results were expected to assist in elucidating the aetiology of conventional OS, and provide more information to assist in the clinical diagnosis and treatment of this disease.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Affymetrix microarray data</title>
<p>The GSE14359 (<xref rid="b8-mmr-16-05-7617" ref-type="bibr">8</xref>) gene expression profile data were acquired from the Gene Expression Omnibus (<uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</uri>), which was based on the platform of the GPL96 [HG-U133A] Affymetrix Human Genome U133A Array. This dataset contains 10 conventional OS samples from the femur or tibia (two replicates each) from five consenting patients with grade 2&#x2013;3 conventional OS between 7 and 74 years of age; eight OS lung metastasis tumour samples (two replicates each) from four consenting patients with a grade 1&#x2013;3 OS lung metastatic tumour; and two non-neoplastic primary osteoblast cell samples with limited life span <italic>in vitro</italic> from one patient (two replicates). These 10 conventional OS samples and two non-neoplastic primary osteoblast samples were selected for further analysis.</p>
<p>The CEL files and probe annotation files were downloaded, and the gene expression data of all samples were preprocessed via background correction, quantile normalization and probe summarization using the Gene Chip Robust Multi Array algorithm (<xref rid="b12-mmr-16-05-7617" ref-type="bibr">12</xref>) in the Affy software package (version 1.32.0; <uri xlink:href="http://www.bioconductor.org/packages/release/bioc/html/affy.html">http://www.bioconductor.org/packages/release/bioc/html/affy.html</uri>) (<xref rid="b13-mmr-16-05-7617" ref-type="bibr">13</xref>).</p>
</sec>
<sec>
<title>DEG screening</title>
<p>The Linear Models for Microarray Data package (version 3.10.3; <uri xlink:href="http://www.bioconductor.org/packages/2.9/bioc/html/limma.html">http://www.bioconductor.org/packages/2.9/bioc/html/limma.html</uri>) (<xref rid="b14-mmr-16-05-7617" ref-type="bibr">14</xref>) of R was used to identify genes, which were significantly differentially expressed in the conventional OS samples. The raw P-value was adjusted by the Benjamin and Hochberg method (<xref rid="b15-mmr-16-05-7617" ref-type="bibr">15</xref>), and only genes meeting the cut-off criteria of |log<sub>2</sub> fold-change|&#x003E;1 and adjusted P&#x003C;0.01 were selected as DEGs.</p>
</sec>
<sec>
<title>Hierarchical clustering analysis of the DEGs</title>
<p>Hierarchical clustering is a common method used to determine clusters of similar data points in multidimensional spaces (<xref rid="b16-mmr-16-05-7617" ref-type="bibr">16</xref>). The pheatmap package (version 1.08; <uri xlink:href="https://cran.r-project.org/web/packages/pheatmap/">https://cran.r-project.org/web/packages/pheatmap/</uri>) (<xref rid="b17-mmr-16-05-7617" ref-type="bibr">17</xref>) was used to perform hierarchical clustering via joint between-within distances for the DEGs in the conventional OS and non-neoplastic primary osteoblasts samples.</p>
</sec>
<sec>
<title>GO and pathway enrichment analyses</title>
<p>The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a set of comprehensive functional annotation tools, which can be used to identify the biological meanings of abundant genes (<xref rid="b18-mmr-16-05-7617" ref-type="bibr">18</xref>). P&#x003C;0.01 was used as the cut-off criterion for GO and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis using DAVID (version 6.7; <uri xlink:href="https://david-d.ncifcrf.gov/">https://david-d.ncifcrf.gov/</uri>), based on the hypergeometric distribution algorithm.</p>
</sec>
<sec>
<title>PPI network construction</title>
<p>The Search Tool for the Retrieval of Interacting Genes database (version 10.0; <uri xlink:href="http://string-db.org/">http://string-db.org/</uri>), which provides experimental and predicted interaction information (<xref rid="b19-mmr-16-05-7617" ref-type="bibr">19</xref>), was used to analyse the PPIs for DEGs by calculating the combined score, and a score &#x003E;0.4 was selected as the cut-off criterion. Subsequently, the PPI network of the upregulated and downregulated DEGs was visualized using Cytoscape (version 3.2.0; <uri xlink:href="http://cytoscape.org/">http://cytoscape.org/</uri>) (<xref rid="b20-mmr-16-05-7617" ref-type="bibr">20</xref>).</p>
</sec>
<sec>
<title>Screening and analysis of network modules</title>
<p>The network modules were obtained based on Molecular Complex Detection (MCODE) analysis (<xref rid="b21-mmr-16-05-7617" ref-type="bibr">21</xref>) of the original PPI networks. The default parameters (degree cut-off, 2; node score cut-off, 0.2; K-core, 2) were used as the cut-off criteria for the network module screening.</p>
<p>In order to obtain further information on the gene functions and identify pathways closely associated with the DEGs, functional annotation analysis and subsequent pathway enrichment analysis of the network module with the highest MCODE score were performed using DAVID, with a P&#x003C;0.01 cut-off.</p>
</sec>
<sec>
<title>Integrated miRNA-DEG regulatory network construction</title>
<p>The potential miRNAs for upregulated DEGs in the most significant pathway were predicted using the miRDB database (version 1.24.0; <uri xlink:href="http://www.bioconductor.org/packages/2.8/bioc/html/maDB.html">http://www.bioconductor.org/packages/2.8/bioc/html/maDB.html</uri>) (<xref rid="b22-mmr-16-05-7617" ref-type="bibr">22</xref>), with a cut-off for the target score of &#x2265;60. The binding sites of miRNAs in the human mRNAs &#x003E; 800 were abandoned. The integrated miRNA-DEG regulatory network was then visualised with Cytoscape.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Identification of DEGs</title>
<p>Following the data preprocessing, 11,107 probes were obtained. Based on the cut-off criteria, a total of 987 DEGs were screened from the conventional OS samples, including 317 upregulated genes and 670 downregulated genes. The hierarchical cluster analysis of the data revealed that it was possible to use the DEGs to accurately distinguish the conventional OS samples from the non-neoplastic primary osteoblast cell samples (<xref rid="f1-mmr-16-05-7617" ref-type="fig">Fig. 1</xref>).</p>
</sec>
<sec>
<title>Enrichment analysis of upregulated and downregulated DEGs</title>
<p>According to the GO functional annotation, the upregulated DEGs were predominantly enriched in GO terms associated with DNA replication, including <italic>MCM3</italic>, replication factor C (<italic>RFC</italic>)<italic>5</italic>, replication protein A3 (<italic>RPA3</italic>) and flap endonuclease 1 (<italic>FEN1</italic>), and cell cycle, including cyclin-dependent kinase 1 (<italic>CDK1</italic>), NDC80 kinetochore complex (<italic>NDC80</italic>), BUB1 mitotic checkpoint serine/threonine-protein kinase (<italic>BUB1</italic>) and mitotic arrest deficient 2 like 1 (<italic>MAD2L1</italic>). A number of downregulated DEGs, including caveolin 1 (<italic>CAV1</italic>), cadherin 13 (<italic>CDH13</italic>), vascular endothelial growth factor C (<italic>VEGFC</italic>) and transforming growth factor &#x03B2; receptor 3 (<italic>TGFBR3</italic>), were relevant to blood vessel development, whereas epidermal growth factor receptor (<italic>EGFR</italic>), <italic>TP53</italic>, <italic>VEGFB</italic> and <italic>MAPK1</italic> were associated with the regulation of cell proliferation (<xref rid="tI-mmr-16-05-7617" ref-type="table">Table IA</xref>).</p>
<p>According to the results of the pathway enrichment analysis, the upregulated DEGs were predominantly enriched in seven pathways. In accordance with the GO term analysis, the DNA replication pathway, including <italic>RFC2</italic>, <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic>, and cell cycle pathway, including <italic>CDK1</italic>, minichromosome maintenance complex component 3 (<italic>MCM3</italic>) and <italic>BUB1</italic>, were also enriched in the upregulated genes. The downregulated DEGs were predominantly enriched in the focal adhesion, including <italic>CAV1</italic>, collagen type VI &#x03B1;1 (<italic>COL6A1</italic>), thrombospondin 1 (<italic>THBS1</italic>) and <italic>EGFR</italic>, and p53 signalling pathways, including <italic>TP53</italic>, Fas cell surface death receptor (<italic>FAS</italic>) and TP53 apoptosis effector (<italic>PERP</italic>), as shown in <xref rid="tI-mmr-16-05-7617" ref-type="table">Table IB</xref>.</p>
</sec>
<sec>
<title>Construction and analysis of the PPI network</title>
<p>The PPI network for the upregulated and downregulated DEGs consisted of 442 pairs of PPIs. The degrees of DEGs, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>NDC80</italic>, non-SMC condensin I complex subunit G (<italic>NCAPG</italic>), <italic>BUB1</italic>, centromere protein F (<italic>CENPF</italic>) and kinesin family member 11 (<italic>KIF11</italic>), were &#x003E;17 (<xref rid="tII-mmr-16-05-7617" ref-type="table">Table II</xref>), indicating that they were important genes in OS.</p>
</sec>
<sec>
<title>Analysis of network modules</title>
<p>A total of 10 network modules were obtained from the PPI network using the default criteria, and the module with the highest score contained 16 nodes and 102 edges. In this module, <italic>CDK1</italic> interacted with other DEGs, including <italic>MAD2L1</italic>, <italic>BUB1</italic>, <italic>NCAPG</italic>, <italic>NDC80</italic> and <italic>CENPF</italic> (<xref rid="f2-mmr-16-05-7617" ref-type="fig">Fig. 2</xref>).</p>
<p>The functional enrichment analysis of the module with the highest score showed that the majority of the DEGs in this module were predominantly associated with the cell cycle. Certain DEGs, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>BUB1</italic> and <italic>NDC80</italic>, were implicated in mitosis and the M phase of mitotic cell cycle; other DEGs, including Rac GTPase-activating protein 1 (<italic>RACGAP1</italic>) and <italic>MAD2L1</italic>, were correlated with cell cycle process (<xref rid="tIII-mmr-16-05-7617" ref-type="table">Table IIIA</xref>). <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>BUB1</italic> and aurora kinase A (<italic>AURKA</italic>) were significantly enriched in the oocyte meiosis pathway (<xref rid="tIII-mmr-16-05-7617" ref-type="table">Table IIIB</xref>).</p>
</sec>
<sec>
<title>Analysis of the miRNA-DEG regulatory network</title>
<p>The miRNA-DEG regulatory network contained 63 miRNAs, nine of their corresponding DEGs and 16 DEGs, which interacted with these nine DEGs. DNA polymerase &#x03B6; subunit 3 (<italic>POLE3</italic>) was regulated by 18 miRNAs, including miR-4310, miR-4680-3p, miR-583 and miR-4269; <italic>RFC3</italic> was regulated by 16 miRNAs, including miR-802 and miR-649; <italic>RFC3</italic> and <italic>RFC5</italic> were modulated by miR-522-3p and miR-224-3p. In addition, <italic>RFC2</italic>, <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic> interacted with each other (<xref rid="f3-mmr-16-05-7617" ref-type="fig">Fig. 3</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>In the present study, 317 DEGs were found to be significantly upregulated and 670 were significantly downregulated in the conventional OS samples. A majority of the DEGs were associated with cell cycle. According to the miRNA-DEG regulatory network for the DEGs enriched in DNA replication, <italic>RFC2</italic>, <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic> were found to interact with each other.</p>
<p><italic>RFC2</italic>, <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic> encode members of RFC family, also termed activator 1. These DEGs were enriched in DNA replication, which agreed with the results of previous studies (<xref rid="b23-mmr-16-05-7617" ref-type="bibr">23</xref>,<xref rid="b24-mmr-16-05-7617" ref-type="bibr">24</xref>). DNA replication is an essential event in tumour growth (<xref rid="b25-mmr-16-05-7617" ref-type="bibr">25</xref>). The deregulation of protein complexes involved in the initiation of DNA replication can lead to cancer (<xref rid="b26-mmr-16-05-7617" ref-type="bibr">26</xref>). Several DEGs in the network module, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>NDC80</italic> and <italic>BUB1</italic>, which had higher degrees in the PPI network, were found to interact with <italic>RFC4</italic>. These four DEGs were predominantly enriched in cell mitosis and cell cycle. Alterations in cell cycle regulation occur in several types of cancer, including OS (<xref rid="b27-mmr-16-05-7617" ref-type="bibr">27</xref>). Cyclin-dependent kinase 1 (CDK1) is an important G2/M checkpoint protein (<xref rid="b28-mmr-16-05-7617" ref-type="bibr">28</xref>), and its inhibitor, SCH 727965 (dinacliclib) can trigger the apoptosis of U-2 OS cells (<xref rid="b29-mmr-16-05-7617" ref-type="bibr">29</xref>). <italic>MAD2L1</italic>, <italic>BUB1</italic> and <italic>NDC80</italic> are involved in the spindle checkpoint pathway (<xref rid="b30-mmr-16-05-7617" ref-type="bibr">30</xref>,<xref rid="b31-mmr-16-05-7617" ref-type="bibr">31</xref>). <italic>MAD2</italic> has been reported to be commonly overexpressed in human conventional OS (<xref rid="b32-mmr-16-05-7617" ref-type="bibr">32</xref>), and <italic>BUB1</italic> has been found to be ectopically expressed in SAOS and U-2 OS cell lines (<xref rid="b33-mmr-16-05-7617" ref-type="bibr">33</xref>). In addition, <italic>CDK1</italic>, <italic>MAD2L1</italic> and <italic>BUB1</italic> have been found to be significantly enriched in the pathway of oocyte meiosis, which was found to be markedly altered in high-grade OS cell lines when compared with osteoblasts (<xref rid="b34-mmr-16-05-7617" ref-type="bibr">34</xref>). <italic>RFC3</italic> was also modulated by a cluster of miRNAs, including miR-802. The expression of miR-802 has been reported to be upregulated in OS tissues, and to promote cell proliferation by targeting p27 in U-2 OS and MG-63 cells (<xref rid="b35-mmr-16-05-7617" ref-type="bibr">35</xref>). <italic>RFC3</italic> and <italic>RFC5</italic> are also modulated by miR-224-3p and miR-522-3p. There is no previous evidence indicating that miR-224-3p and miR-522-3p are associated with conventional OS. Therefore, miR-224-3p and miR-522-3p are predicted to be novel biomarkers in conventional OS. Therefore, <italic>RFC2-5</italic>, together with certain DEGs, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>NDC80</italic> and <italic>BUB1</italic>, and a series of miRNAs, including miR-802, miR-224-3p and miR-522-3p, may be responsible for the initiation and development of conventional OS.</p>
<p>In conclusion, the present study found that the majority of DEGs, including <italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>NDC80</italic> and <italic>BUB1</italic>, were associated with the cell cycle. Other DEGs, including <italic>RFC2</italic>, <italic>RFC3</italic>, <italic>RFC4</italic> and <italic>RFC5</italic>, were associated with DNA replication. These, in addition to a number of miRNAs, including miR-802, miR-224-3p and miR-522-3p, may be essential in the pathogenesis of conventional OS, providing novel information to assist in the clinical diagnosis of this disease. However due to limitations in the present study, additional experiments are required to shed light on the molecular mechanisms involved in this life-threatening disease.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-16-05-7617"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messerschmitt</surname><given-names>PJ</given-names></name><name><surname>Garcia</surname><given-names>RM</given-names></name><name><surname>Abdul-Karim</surname><given-names>FW</given-names></name><name><surname>Greenfield</surname><given-names>EM</given-names></name><name><surname>Getty</surname><given-names>PJ</given-names></name></person-group><article-title>Osteosarcoma</article-title><source>J Am Acad Orthop Surg</source><volume>17</volume><fpage>515</fpage><lpage>527</lpage><year>2009</year><pub-id pub-id-type="doi">10.5435/00124635-200908000-00005</pub-id><pub-id pub-id-type="pmid">19652033</pub-id></element-citation></ref>
<ref id="b2-mmr-16-05-7617"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohseny</surname><given-names>AB</given-names></name><name><surname>Tieken</surname><given-names>C</given-names></name><name><surname>Van Der Velden</surname><given-names>PA</given-names></name><name><surname>Szuhai</surname><given-names>K</given-names></name><name><surname>de Andrea</surname><given-names>C</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>Cleton-Jansen</surname><given-names>AM</given-names></name></person-group><article-title>Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma</article-title><source>Genes Chromosomes Cancer</source><volume>49</volume><fpage>1095</fpage><lpage>1103</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/gcc.20817</pub-id><pub-id pub-id-type="pmid">20737480</pub-id></element-citation></ref>
<ref id="b3-mmr-16-05-7617"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Zeng</surname><given-names>HC</given-names></name><name><surname>Campeau</surname><given-names>PM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bertin</surname><given-names>T</given-names></name><name><surname>Dawson</surname><given-names>BC</given-names></name><name><surname>Munivez</surname><given-names>E</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name></person-group><article-title>miRNA-34c regulates Notch signaling during bone development</article-title><source>Hum Mol Genet</source><volume>21</volume><fpage>2991</fpage><lpage>3000</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/hmg/dds129</pub-id><pub-id pub-id-type="pmid">22498974</pub-id><pub-id pub-id-type="pmcid">3373245</pub-id></element-citation></ref>
<ref id="b4-mmr-16-05-7617"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Yunes</surname><given-names>JA</given-names></name><name><surname>Cardoso</surname><given-names>BA</given-names></name><name><surname>Martins</surname><given-names>LR</given-names></name><name><surname>Jotta</surname><given-names>PY</given-names></name><name><surname>Abecasis</surname><given-names>M</given-names></name><name><surname>Nowill</surname><given-names>AE</given-names></name><name><surname>Leslie</surname><given-names>NR</given-names></name><name><surname>Cardoso</surname><given-names>AA</given-names></name><name><surname>Barata</surname><given-names>JT</given-names></name></person-group><article-title>PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability</article-title><source>J Clin Invest</source><volume>118</volume><fpage>3762</fpage><lpage>3774</lpage><year>2008</year><pub-id pub-id-type="doi">10.1172/JCI34616</pub-id><pub-id pub-id-type="pmid">18830414</pub-id><pub-id pub-id-type="pmcid">2556239</pub-id></element-citation></ref>
<ref id="b5-mmr-16-05-7617"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>SS</given-names></name><name><surname>Allen</surname><given-names>SW</given-names></name><name><surname>Ganti</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Dome</surname><given-names>JS</given-names></name><name><surname>Daw</surname><given-names>NC</given-names></name><name><surname>Khoury</surname><given-names>JD</given-names></name></person-group><article-title>Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors</article-title><source>Cancer</source><volume>113</volume><fpage>1453</fpage><lpage>1461</lpage><year>2008</year><pub-id pub-id-type="doi">10.1002/cncr.23782</pub-id><pub-id pub-id-type="pmid">18704985</pub-id><pub-id pub-id-type="pmcid">3529469</pub-id></element-citation></ref>
<ref id="b6-mmr-16-05-7617"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><etal/></person-group><article-title>MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma</article-title><source>PLoS One</source><volume>8</volume><fpage>e53906</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0053906</pub-id><pub-id pub-id-type="pmid">23372675</pub-id><pub-id pub-id-type="pmcid">3553141</pub-id></element-citation></ref>
<ref id="b7-mmr-16-05-7617"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naml&#x00F8;s</surname><given-names>HM</given-names></name><name><surname>Meza-Zepeda</surname><given-names>LA</given-names></name><name><surname>Bar&#x00F8;y</surname><given-names>T</given-names></name><name><surname>&#x00D8;stensen</surname><given-names>IH</given-names></name><name><surname>Kresse</surname><given-names>SH</given-names></name><name><surname>Kuijjer</surname><given-names>ML</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>B&#x00FC;rger</surname><given-names>H</given-names></name><name><surname>Cleton-Jansen</surname><given-names>AM</given-names></name><name><surname>Myklebost</surname><given-names>O</given-names></name></person-group><article-title>Modulation of the osteosarcoma expression phenotype by microRNAs</article-title><source>PLoS One</source><volume>7</volume><fpage>e48086</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0048086</pub-id><pub-id pub-id-type="pmid">23133552</pub-id><pub-id pub-id-type="pmcid">3485010</pub-id></element-citation></ref>
<ref id="b8-mmr-16-05-7617"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche-Guenther</surname><given-names>R</given-names></name><name><surname>Noske</surname><given-names>A</given-names></name><name><surname>Ungeth&#x00FC;m</surname><given-names>U</given-names></name><name><surname>Kuban</surname><given-names>RJ</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Tunn</surname><given-names>PU</given-names></name><name><surname>Karle</surname><given-names>J</given-names></name><name><surname>Krenn</surname><given-names>V</given-names></name><name><surname>Dietel</surname><given-names>M</given-names></name><name><surname>Sers</surname><given-names>C</given-names></name></person-group><article-title>De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway</article-title><source>Histopathology</source><volume>57</volume><fpage>836</fpage><lpage>850</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1365-2559.2010.03713.x</pub-id><pub-id pub-id-type="pmid">21166698</pub-id></element-citation></ref>
<ref id="b9-mmr-16-05-7617"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritsche-Guenther</surname><given-names>R</given-names></name><name><surname>Gruetzkau</surname><given-names>A</given-names></name><name><surname>Noske</surname><given-names>A</given-names></name><name><surname>Melcher</surname><given-names>I</given-names></name><name><surname>Schaser</surname><given-names>KD</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Kasper</surname><given-names>HU</given-names></name><name><surname>Krenn</surname><given-names>V</given-names></name><name><surname>Sers</surname><given-names>C</given-names></name></person-group><article-title>Therapeutic potential of CAMPATH-1H in skeletal tumours</article-title><source>Histopathology</source><volume>57</volume><fpage>851</fpage><lpage>861</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1365-2559.2010.03722.x</pub-id><pub-id pub-id-type="pmid">21166699</pub-id></element-citation></ref>
<ref id="b10-mmr-16-05-7617"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Pivotal regulatory network and genes in osteosarcoma</article-title><source>Arch Med Sci</source><volume>9</volume><fpage>569</fpage><lpage>575</lpage><year>2013</year><pub-id pub-id-type="doi">10.5114/aoms.2012.30956</pub-id><pub-id pub-id-type="pmid">23847684</pub-id></element-citation></ref>
<ref id="b11-mmr-16-05-7617"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data</article-title><source>BMC Med Genet</source><volume>15</volume><fpage>80</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2350-15-80</pub-id><pub-id pub-id-type="pmid">25023069</pub-id><pub-id pub-id-type="pmcid">4109777</pub-id></element-citation></ref>
<ref id="b12-mmr-16-05-7617"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Gentleman</surname><given-names>R</given-names></name><name><surname>Martinez-Murillo</surname><given-names>F</given-names></name><name><surname>Spencer</surname><given-names>F</given-names></name></person-group><article-title>A model-based background adjustment for oligonucleotide expression arrays</article-title><source>Journal of the American Statistical Association</source><volume>99</volume><fpage>909</fpage><lpage>917</lpage><year>2004</year><pub-id pub-id-type="doi">10.1198/016214504000000683</pub-id></element-citation></ref>
<ref id="b13-mmr-16-05-7617"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Hoffman</surname><given-names>EP</given-names></name></person-group><article-title>Probe set algorithms: Is there a rational best bet?</article-title><source>BMC bioinformatics</source><volume>7</volume><fpage>395</fpage><year>2006</year><pub-id pub-id-type="doi">10.1186/1471-2105-7-395</pub-id><pub-id pub-id-type="pmid">16942624</pub-id><pub-id pub-id-type="pmcid">1569879</pub-id></element-citation></ref>
<ref id="b14-mmr-16-05-7617"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title><source>Stat Appl Genet Mol Biol</source><volume>3</volume><fpage>Article3</fpage><year>2004</year><pub-id pub-id-type="doi">10.2202/1544-6115.1027</pub-id><pub-id pub-id-type="pmid">16646809</pub-id></element-citation></ref>
<ref id="b15-mmr-16-05-7617"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society Series B (Methodological)</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><year>1995</year></element-citation></ref>
<ref id="b16-mmr-16-05-7617"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>CF</given-names></name></person-group><article-title>Parallel algorithms for hierarchical clustering</article-title><source>Parallel Computing</source><volume>21</volume><fpage>1313</fpage><lpage>1325</lpage><year>1995</year><pub-id pub-id-type="doi">10.1016/0167-8191(95)00017-I</pub-id></element-citation></ref>
<ref id="b17-mmr-16-05-7617"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolde</surname><given-names>R</given-names></name></person-group><article-title>pheatmap: Pretty Heatmaps</article-title><source>R package</source><comment>version 0.7. 7</comment><year>2012</year></element-citation></ref>
<ref id="b18-mmr-16-05-7617"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>JR</given-names></name><name><surname>Alvord</surname><given-names>WG</given-names></name><name><surname>Roayaei</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>R</given-names></name><name><surname>Baseler</surname><given-names>MW</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists</article-title><source>Genome Biol</source><volume>8</volume><fpage>R183</fpage><year>2007</year><pub-id pub-id-type="doi">10.1186/gb-2007-8-9-r183</pub-id><pub-id pub-id-type="pmid">17784955</pub-id><pub-id pub-id-type="pmcid">2375021</pub-id></element-citation></ref>
<ref id="b19-mmr-16-05-7617"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Mering</surname><given-names>C</given-names></name><name><surname>Huynen</surname><given-names>M</given-names></name><name><surname>Jaeggi</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Snel</surname><given-names>B</given-names></name></person-group><article-title>STRING: A database of predicted functional associations between proteins</article-title><source>Nucleic Acids Res</source><volume>31</volume><fpage>258</fpage><lpage>261</lpage><year>2003</year><pub-id pub-id-type="doi">10.1093/nar/gkg034</pub-id><pub-id pub-id-type="pmid">12519996</pub-id><pub-id pub-id-type="pmcid">165481</pub-id></element-citation></ref>
<ref id="b20-mmr-16-05-7617"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>M</given-names></name><name><surname>Wiese</surname><given-names>S</given-names></name><name><surname>Warscheid</surname><given-names>B</given-names></name></person-group><article-title>Cytoscape: Software for visualization and analysis of biological networks</article-title><source>Methods Mol Biol</source><volume>696</volume><fpage>291</fpage><lpage>303</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/978-1-60761-987-1_18</pub-id><pub-id pub-id-type="pmid">21063955</pub-id></element-citation></ref>
<ref id="b21-mmr-16-05-7617"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Hogue</surname><given-names>CW</given-names></name></person-group><article-title>An automated method for finding molecular complexes in large protein interaction networks</article-title><source>BMC bioinformatics</source><volume>4</volume><fpage>2</fpage><year>2003</year><pub-id pub-id-type="doi">10.1186/1471-2105-4-2</pub-id><pub-id pub-id-type="pmid">12525261</pub-id><pub-id pub-id-type="pmcid">149346</pub-id></element-citation></ref>
<ref id="b22-mmr-16-05-7617"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: A microRNA target prediction and functional annotation database with a wiki interface</article-title><source>RNA</source><volume>14</volume><fpage>1012</fpage><lpage>1017</lpage><year>2008</year><pub-id pub-id-type="doi">10.1261/rna.965408</pub-id><pub-id pub-id-type="pmid">18426918</pub-id><pub-id pub-id-type="pmcid">2390791</pub-id></element-citation></ref>
<ref id="b23-mmr-16-05-7617"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>N</given-names></name><name><surname>Fantes</surname><given-names>PA</given-names></name><name><surname>MacNeill</surname><given-names>SA</given-names></name></person-group><article-title>A key role for replication factor C in DNA replication checkpoint function in fission yeast</article-title><source>Nucleic Acids Res</source><volume>27</volume><fpage>462</fpage><lpage>469</lpage><year>1999</year><pub-id pub-id-type="doi">10.1093/nar/27.2.462</pub-id><pub-id pub-id-type="pmid">9862966</pub-id><pub-id pub-id-type="pmcid">148201</pub-id></element-citation></ref>
<ref id="b24-mmr-16-05-7617"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo-Mu&#x00F1;oz</surname><given-names>J</given-names></name><name><surname>Rodr&#x00ED;guez</surname><given-names>MJ</given-names></name><name><surname>Sili&#x00F3;</surname><given-names>V</given-names></name><name><surname>P&#x00E9;rez-Garc&#x00ED;a</surname><given-names>V</given-names></name><name><surname>Valpuesta</surname><given-names>JM</given-names></name><name><surname>Carrera</surname><given-names>AC</given-names></name></person-group><article-title>Phosphoinositide 3-kinase beta controls replication factor C assembly and function</article-title><source>Nucleic Acids Res</source><volume>41</volume><fpage>855</fpage><lpage>868</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/nar/gks1095</pub-id><pub-id pub-id-type="pmid">23175608</pub-id></element-citation></ref>
<ref id="b25-mmr-16-05-7617"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>LA</given-names></name><name><surname>Springgate</surname><given-names>CF</given-names></name><name><surname>Battula</surname><given-names>N</given-names></name></person-group><article-title>Errors in DNA replication as a basis of malignant changes</article-title><source>Cancer Res</source><volume>34</volume><fpage>2311</fpage><lpage>2321</lpage><year>1974</year><pub-id pub-id-type="pmid">4136142</pub-id></element-citation></ref>
<ref id="b26-mmr-16-05-7617"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsaniras</surname><given-names>S Champeris</given-names></name><name><surname>Kanellakis</surname><given-names>N</given-names></name><name><surname>Symeonidou</surname><given-names>IE</given-names></name><name><surname>Nikolopoulou</surname><given-names>P</given-names></name><name><surname>Lygerou</surname><given-names>Z</given-names></name><name><surname>Taraviras</surname><given-names>S</given-names></name></person-group><article-title>Licensing of DNA replication, cancer, pluripotency and differentiation: An interlinked world?</article-title><source>Semin Cell Dev Biol</source><volume>30</volume><fpage>174</fpage><lpage>180</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.semcdb.2014.03.013</pub-id><pub-id pub-id-type="pmid">24641889</pub-id></element-citation></ref>
<ref id="b27-mmr-16-05-7617"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>PosthumaDeBoer</surname><given-names>J</given-names></name><name><surname>van Royen</surname><given-names>B</given-names></name><name><surname>Helder</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of therapy resistance in osteosarcoma: A review</article-title><source>Oncol Discov</source><volume>1</volume><fpage>8</fpage><year>2013</year><pub-id pub-id-type="doi">10.7243/2052-6199-1-8</pub-id></element-citation></ref>
<ref id="b28-mmr-16-05-7617"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name></person-group><article-title>Transient suppression of nuclear Cdc2 activity in response to ionizing radiation</article-title><source>Oncol Rep</source><volume>19</volume><fpage>1323</fpage><lpage>1329</lpage><year>2008</year><pub-id pub-id-type="pmid">18425394</pub-id></element-citation></ref>
<ref id="b29-mmr-16-05-7617"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bui</surname><given-names>MM</given-names></name><name><surname>Gemmer</surname><given-names>J</given-names></name><name><surname>Altiok</surname><given-names>S</given-names></name><name><surname>Pledger</surname><given-names>WJ</given-names></name></person-group><article-title>The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells</article-title><source>Mol Cancer Ther</source><volume>10</volume><fpage>1018</fpage><lpage>1027</lpage><year>2011</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0167</pub-id><pub-id pub-id-type="pmid">21490307</pub-id><pub-id pub-id-type="pmcid">4727401</pub-id></element-citation></ref>
<ref id="b30-mmr-16-05-7617"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doak</surname><given-names>SH</given-names></name><name><surname>Jenkins</surname><given-names>GJ</given-names></name><name><surname>Parry</surname><given-names>EM</given-names></name><name><surname>Griffiths</surname><given-names>AP</given-names></name><name><surname>Baxter</surname><given-names>JN</given-names></name><name><surname>Parry</surname><given-names>JM</given-names></name></person-group><article-title>Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett&#x0027;s oesophagus-their association with aneuploidy and neoplastic progression</article-title><source>Mutat Res</source><volume>547</volume><fpage>133</fpage><lpage>144</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2003.12.009</pub-id><pub-id pub-id-type="pmid">15013707</pub-id></element-citation></ref>
<ref id="b31-mmr-16-05-7617"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giantin</surname><given-names>M</given-names></name><name><surname>Granato</surname><given-names>A</given-names></name><name><surname>Baratto</surname><given-names>C</given-names></name><name><surname>Marconato</surname><given-names>L</given-names></name><name><surname>Vascellari</surname><given-names>M</given-names></name><name><surname>Morello</surname><given-names>EM</given-names></name><name><surname>Vercelli</surname><given-names>A</given-names></name><name><surname>Mutinelli</surname><given-names>F</given-names></name><name><surname>Dacasto</surname><given-names>M</given-names></name></person-group><article-title>Global gene expression analysis of canine cutaneous mast cell tumor: Could molecular profiling be useful for subtype classification and prognostication?</article-title><source>PLoS One</source><volume>9</volume><fpage>e95481</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0095481</pub-id><pub-id pub-id-type="pmid">24748173</pub-id><pub-id pub-id-type="pmcid">3991658</pub-id></element-citation></ref>
<ref id="b32-mmr-16-05-7617"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>WC</given-names></name><name><surname>Zhao</surname><given-names>SH</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name></person-group><article-title>Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma</article-title><source>Apmis</source><volume>118</volume><fpage>222</fpage><lpage>229</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1600-0463.2009.02583.x</pub-id><pub-id pub-id-type="pmid">20132188</pub-id></element-citation></ref>
<ref id="b33-mmr-16-05-7617"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trougakos</surname><given-names>IP</given-names></name><name><surname>Chondrogianni</surname><given-names>N</given-names></name><name><surname>Amarantos</surname><given-names>I</given-names></name><name><surname>Blake</surname><given-names>J</given-names></name><name><surname>Schwager</surname><given-names>C</given-names></name><name><surname>Wirkner</surname><given-names>U</given-names></name><name><surname>Ansorge</surname><given-names>W</given-names></name><name><surname>Gonos</surname><given-names>ES</given-names></name></person-group><article-title>Genome-wide transcriptome profile of the human osteosarcoma Sa OS and U-2 OS cell lines</article-title><source>Cancer Genet Cytogenet</source><volume>196</volume><fpage>109</fpage><lpage>118</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2009.09.012</pub-id><pub-id pub-id-type="pmid">20082845</pub-id></element-citation></ref>
<ref id="b34-mmr-16-05-7617"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuijjer</surname><given-names>ML</given-names></name><name><surname>Peterse</surname><given-names>EF</given-names></name><name><surname>van den Akker</surname><given-names>BE</given-names></name><name><surname>Briaire-de Bruijn</surname><given-names>IH</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Meza-Zepeda</surname><given-names>LA</given-names></name><name><surname>Myklebost</surname><given-names>O</given-names></name><name><surname>Hassan</surname><given-names>AB</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>Cleton-Jansen</surname><given-names>AM</given-names></name></person-group><article-title>IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma</article-title><source>BMC Cancer</source><volume>13</volume><fpage>245</fpage><year>2013</year><pub-id pub-id-type="doi">10.1186/1471-2407-13-245</pub-id><pub-id pub-id-type="pmid">23688189</pub-id><pub-id pub-id-type="pmcid">3672007</pub-id></element-citation></ref>
<ref id="b35-mmr-16-05-7617"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>ZQ</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>WY</given-names></name></person-group><article-title>MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27</article-title><source>Asian Pac J Cancer Prev</source><volume>14</volume><fpage>7081</fpage><lpage>7084</lpage><year>2013</year><pub-id pub-id-type="doi">10.7314/APJCP.2013.14.12.7081</pub-id><pub-id pub-id-type="pmid">24460254</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-16-05-7617" position="float">
<label>Figure 1.</label>
<caption><p>Hierarchical clustering analysis of the differentially expressed genes in the conventional OS samples and non-neoplastic primary osteoblasts samples. Each row represents a single gene; each column represents a tissue sample. The gradual color change from green to red represents the change from upregulation to downregulation. R1 and R2 indicate two replicates of one sample. OS, osteosarcoma; Nor, non-neoplastic primary osteoblast sample; OS1-OS5, conventional OS samples.</p></caption>
<graphic xlink:href="MMR-16-05-7617-g00.tif"/>
</fig>
<fig id="f2-mmr-16-05-7617" position="float">
<label>Figure 2.</label>
<caption><p>Modules with the highest significance in the protein-protein interaction network. The lines between any nodes represent the interrelations of those proteins.</p></caption>
<graphic xlink:href="MMR-16-05-7617-g01.tif"/>
</fig>
<fig id="f3-mmr-16-05-7617" position="float">
<label>Figure 3.</label>
<caption><p>Regulatory network containing microRNAs and their corresponding differentially expressed genes enriched in the DNA replication pathway. Large circular nodes represent upregulated genes enriched in the DNA replication pathway; small circular nodes represent genes interacting with the genes enriched in the DNA replication pathway; rectangular nodes represent microRNAs. miR, microRNA.</p></caption>
<graphic xlink:href="MMR-16-05-7617-g02.tif"/>
</fig>
<table-wrap id="tI-mmr-16-05-7617" position="float">
<label>Table I.</label>
<caption><p>GO terms and pathways enriched for the upregulated and downregulated DEGs.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom" colspan="6">A, Top 10 GO terms for the upregulated and downregulated DEGs</th>
</tr>
<tr>
<th align="center" valign="bottom" colspan="6"><hr/></th>
</tr>
<tr>
<th align="left" valign="bottom">Category</th>
<th align="center" valign="bottom">Term</th>
<th align="center" valign="bottom">Description</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">n</th>
<th align="center" valign="bottom">Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Up</td>
<td align="center" valign="top">GO:0006259</td>
<td align="left" valign="top">DNA metabolic process</td>
<td align="center" valign="top">8.09E-13</td>
<td align="center" valign="top">38</td>
<td align="left" valign="top"><italic>RPA3</italic>, <italic>FANCL</italic>, <italic>FEN1</italic>, <italic>DTL</italic>, <italic>CENPF</italic>, <italic>MCM3</italic>, <italic>RFC5</italic>, <italic>RFC3</italic>, <italic>RFC4</italic>, <italic>RFC2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0006260</td>
<td align="left" valign="top">DNA replication</td>
<td align="center" valign="top">3.90E-10</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>DTL</italic>, <italic>CENPF</italic>, <italic>MCM3</italic>, <italic>RPA3</italic>, <italic>RFC5</italic>, <italic>RFC3</italic>, <italic>RFC4</italic>, <italic>RFC2</italic>, <italic>RRM2</italic>, <italic>FEN1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0022403</td>
<td align="left" valign="top">Cell cycle phase</td>
<td align="center" valign="top">8.15E-10</td>
<td align="center" valign="top">30</td>
<td align="left" valign="top"><italic>AURKA</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic>, <italic>CDK1</italic>, <italic>KIF11</italic>, <italic>DLGAP5</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>MAD2L1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0000278</td>
<td align="left" valign="top">Mitotic cell cycle</td>
<td align="center" valign="top">1.34E-09</td>
<td align="center" valign="top">28</td>
<td align="left" valign="top"><italic>NCAPG</italic>, <italic>BUB1</italic>, <italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>CDKN3</italic>, <italic>MAD2L1</italic>, <italic>ZWINT</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0051301</td>
<td align="left" valign="top">Cell division</td>
<td align="center" valign="top">1.36E-09</td>
<td align="center" valign="top">25</td>
<td align="left" valign="top"><italic>NCAPG</italic>, <italic>BUB1</italic>, <italic>ASPM</italic>, <italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>MCM5</italic>, <italic>MAD2L1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0000280</td>
<td align="left" valign="top">Nuclear division</td>
<td align="center" valign="top">5.16E-09</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>CDC23</italic>, <italic>NDC80</italic>, <italic>BIRC5</italic>, <italic>SMC4</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0007067</td>
<td align="left" valign="top">Mitosis</td>
<td align="center" valign="top">5.16E-09</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>CDC23</italic>, <italic>NDC80</italic>, <italic>BIRC5</italic>, <italic>SMC4</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0000087</td>
<td align="left" valign="top">M phase of mitotic cell cycle</td>
<td align="center" valign="top">7.03E-09</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>CDC23</italic>, <italic>NDC80</italic>, <italic>BIRC5</italic>, <italic>SMC4</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0048285</td>
<td align="left" valign="top">Organelle fission</td>
<td align="center" valign="top">1.03E-08</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>CENPF</italic>, <italic>CDC23</italic>, <italic>NDC80</italic>, <italic>BIRC5</italic>, <italic>SMC4</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0000279</td>
<td align="left" valign="top">M phase</td>
<td align="center" valign="top">1.18E-08</td>
<td align="center" valign="top">25</td>
<td align="left" valign="top"><italic>NCAPG</italic>, <italic>BUB1</italic>, <italic>CDK1</italic>, <italic>KIF11</italic>, <italic>DLGAP5</italic>, <italic>CDC23</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>MAD2L1</italic></td>
</tr>
<tr>
<td align="left" valign="top">Down</td>
<td align="center" valign="top">GO:0001568</td>
<td align="left" valign="top">Blood vessel development</td>
<td align="center" valign="top">1.57E-06</td>
<td align="center" valign="top">28</td>
<td align="left" valign="top"><italic>CAV1</italic>, <italic>THBS1</italic>, <italic>MMP14</italic>, <italic>PNPLA6</italic>, <italic>CDH13</italic>, <italic>VEGFC</italic>, <italic>NTRK2</italic>, <italic>TGFBR3</italic>, <italic>ENG</italic>, <italic>TNFAIP2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0042127</td>
<td align="left" valign="top">Regulation of cell proliferation</td>
<td align="center" valign="top">1.63E-06</td>
<td align="center" valign="top">60</td>
<td align="left" valign="top"><italic>EGFR</italic>, <italic>CTBP1</italic>, <italic>TP53</italic>, <italic>MFGE8</italic>, <italic>HOXC10</italic>, <italic>VEGFB</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic>, <italic>SMAD3</italic>, <italic>SMAD2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0007242</td>
<td align="left" valign="top">Intracellular signaling cascade</td>
<td align="center" valign="top">2.08E-06</td>
<td align="center" valign="top">84</td>
<td align="left" valign="top"><italic>RRAS</italic>, <italic>TP53</italic>, <italic>CAV1</italic>, <italic>MAPKAPK3</italic>, <italic>FHL2</italic>, <italic>TGFBR3</italic>, <italic>GRK5</italic>, <italic>ABL1</italic>, <italic>CRK</italic>, <italic>IGFBP5</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0010033</td>
<td align="left" valign="top">Response to organic substance</td>
<td align="center" valign="top">2.28E-06</td>
<td align="center" valign="top">56</td>
<td align="left" valign="top"><italic>TIMP3</italic>, <italic>STAT6</italic>, <italic>SRR</italic>, <italic>PPP3CB</italic>, <italic>COL6A2</italic>, <italic>SMAD2</italic>, <italic>CDH13</italic>, <italic>ADCY9</italic>, <italic>SMPD1</italic>, <italic>TGFBR3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0051270</td>
<td align="left" valign="top">Regulation of cell motion</td>
<td align="center" valign="top">2.47E-06</td>
<td align="center" valign="top">24</td>
<td align="left" valign="top"><italic>SMAD3</italic>, <italic>ACTN1</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic>, <italic>SEMA3F</italic>, <italic>TGFBR3</italic>, <italic>RRAS</italic>, <italic>THBS1</italic>, <italic>IGFBP3</italic>, <italic>IGFBP5</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0001944</td>
<td align="left" valign="top">Vasculature development</td>
<td align="center" valign="top">2.52E-06</td>
<td align="center" valign="top">28</td>
<td align="left" valign="top"><italic>CAV1</italic>, <italic>MYH9</italic>, <italic>MMP14</italic>, <italic>PNPLA6</italic>, <italic>CDH13</italic>, <italic>VEGFC</italic>, <italic>NTRK2</italic>, <italic>TGFBR3</italic>, <italic>ENG</italic>, <italic>TNFAIP2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0008285</td>
<td align="left" valign="top">Negative regulation of cell proliferation</td>
<td align="center" valign="top">7.25E-06</td>
<td align="center" valign="top">34</td>
<td align="left" valign="top"><italic>CAV1</italic>, <italic>TP53</italic>, <italic>SMAD3</italic>, <italic>SMAD2</italic>, <italic>TGFBR3</italic>, <italic>ADAMTS1</italic>, <italic>IGFBP3</italic>, <italic>ENG</italic>, <italic>IGFBP5</italic>, <italic>TOB1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0040007</td>
<td align="left" valign="top">Growth</td>
<td align="center" valign="top">1.22E-05</td>
<td align="center" valign="top">22</td>
<td align="left" valign="top"><italic>SMAD2</italic>, <italic>LAMB2</italic>, <italic>NUPR1</italic>, <italic>DHCR7</italic>, <italic>SERPINE1</italic>, <italic>TGFBR3</italic>, <italic>BIN3</italic>, <italic>ADD1</italic>, <italic>IGFBP5</italic>, <italic>ERCC2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0030334</td>
<td align="left" valign="top">Regulation of cell migration</td>
<td align="center" valign="top">1.24E-05</td>
<td align="center" valign="top">21</td>
<td align="left" valign="top"><italic>EGFR</italic>, <italic>SMAD3</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic>, <italic>PTP4A1</italic>, <italic>RRAS</italic>, <italic>TGFBR3</italic>, <italic>THBS1</italic>, <italic>IGFBP3</italic>, <italic>IGFBP5</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">GO:0048514</td>
<td align="left" valign="top">Blood vessel morphogenesis</td>
<td align="center" valign="top">3.44E-05</td>
<td align="center" valign="top">23</td>
<td align="left" valign="top"><italic>CAV1</italic>, <italic>CDH13</italic>, <italic>VEGFC</italic>, <italic>SEMA3C</italic>, <italic>PLCD1</italic>, <italic>NR2F2</italic>, <italic>THBS1</italic>, <italic>TNFAIP2</italic>, <italic>ENG</italic>, <italic>CYR61</italic></td>
</tr>
<tr>
<td align="center" valign="top" colspan="6"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="6">B, Pathways enriched for the upregulated and downregulated DEGs</td>
</tr>
<tr>
<td align="center" valign="top" colspan="6"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Category</td>
<td align="center" valign="top">Term</td>
<td align="center" valign="top">Description</td>
<td align="center" valign="top">P-value</td>
<td align="center" valign="top">n</td>
<td align="center" valign="top">Genes</td>
</tr>
<tr>
<td align="center" valign="top" colspan="6"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Up</td>
<td align="center" valign="top">hsa03030</td>
<td align="left" valign="top">DNA replication</td>
<td align="center" valign="top">1.50E-06</td>
<td align="center" valign="top">&#x00A0;&#x00A0;9</td>
<td align="left" valign="top"><italic>RFC5</italic>, <italic>RFC3</italic>, <italic>RFC4</italic>, <italic>POLE3</italic>, <italic>RFC2</italic>, <italic>MCM3</italic>, <italic>FEN1</italic>, <italic>MCM5</italic>, <italic>RPA3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04110</td>
<td align="left" valign="top">Cell cycle</td>
<td align="center" valign="top">1.77E-04</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top"><italic>CDC7</italic>, <italic>CDK1</italic>, <italic>CDKN1B</italic>, <italic>MAD2L1</italic>, <italic>CREBBP</italic>, <italic>BUB1</italic>, <italic>PRKDC</italic>, <italic>CDC23</italic>, <italic>MCM3</italic>, <italic>SMC1A</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa03040</td>
<td align="left" valign="top">Spliceosome</td>
<td align="center" valign="top">1.90E-04</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top"><italic>RBM22</italic>, <italic>HNRNPA3</italic>, <italic>SF3B1</italic>, <italic>SNRPA1</italic>, <italic>MAGOH</italic>, <italic>TRA2B</italic>, <italic>SNRNP200</italic>, <italic>LSM5</italic>, <italic>LSM3</italic>, <italic>SNRPE</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa03430</td>
<td align="left" valign="top">Mismatch repair</td>
<td align="center" valign="top">1.96E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;5</td>
<td align="left" valign="top"><italic>RFC5</italic>, <italic>RFC3</italic>, <italic>RFC4</italic>, <italic>RFC2</italic>, <italic>RPA3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa03420</td>
<td align="left" valign="top">Nucleotide excision repair</td>
<td align="center" valign="top">3.76E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;6</td>
<td align="left" valign="top"><italic>RFC5</italic>, <italic>RFC3</italic>, <italic>RFC4</italic>, <italic>POLE3</italic>, <italic>RFC2</italic>, <italic>RPA3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04114</td>
<td align="left" valign="top">Oocyte meiosis</td>
<td align="center" valign="top">4.63E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;9</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>SLK</italic>, <italic>BUB1</italic>, <italic>CDC23</italic>, <italic>AURKA</italic>, <italic>PPP1CC</italic>, <italic>SMC1A</italic>, <italic>PPP1CB</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa03410</td>
<td align="left" valign="top">Base excision repair</td>
<td align="center" valign="top">9.30E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;5</td>
<td align="left" valign="top"><italic>HMGB1</italic>, <italic>POLE3</italic>, <italic>TDG</italic>, <italic>POLB</italic>, <italic>FEN1</italic></td>
</tr>
<tr>
<td align="left" valign="top">Down</td>
<td align="center" valign="top">hsa04510</td>
<td align="left" valign="top">Focal adhesion</td>
<td align="center" valign="top">4.08E-07</td>
<td align="center" valign="top">29</td>
<td align="left" valign="top"><italic>CAV1</italic>, <italic>COL6A1</italic>, <italic>THBS1</italic>, <italic>FN1</italic>, <italic>EGFR</italic>, <italic>FLNC</italic>, <italic>VEGFB</italic>, <italic>LAMA2</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04142</td>
<td align="left" valign="top">Lysosome</td>
<td align="center" valign="top">1.74E-04</td>
<td align="center" valign="top">17</td>
<td align="left" valign="top"><italic>SGSH</italic>, <italic>CLN3</italic>, <italic>NAGLU</italic>, <italic>PLA2G15</italic>, <italic>CLTB</italic>, <italic>PSAP</italic>, <italic>CTSA</italic>, <italic>GLB1</italic>, <italic>DNASE2</italic>, <italic>LAMP1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04520</td>
<td align="left" valign="top">Adherens junction</td>
<td align="center" valign="top">3.35E-04</td>
<td align="center" valign="top">13</td>
<td align="left" valign="top"><italic>EGFR</italic>, <italic>WASF3</italic>, <italic>SMAD3</italic>, <italic>SMAD2</italic>, <italic>CTNNA1</italic>, <italic>TCF7L1</italic>, <italic>CSNK2A2</italic>, <italic>MAPK1</italic>, <italic>FYN</italic>, <italic>MAPK3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04115</td>
<td align="left" valign="top">p53 signaling pathway</td>
<td align="center" valign="top">4.26E-04</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top"><italic>CCND1</italic>, <italic>TNFRSF10B</italic>, <italic>ZMAT3</italic>, <italic>SERPINE1</italic>, <italic>DDB2</italic>, <italic>TP53</italic>, <italic>FAS</italic>, <italic>PERP</italic>, <italic>THBS1</italic>, <italic>IGFBP3</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa05219</td>
<td align="left" valign="top">Bladder cancer</td>
<td align="center" valign="top">8.61E-04</td>
<td align="center" valign="top">&#x00A0;&#x00A0;9</td>
<td align="left" valign="top"><italic>EGFR</italic>, <italic>VEGFB</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic>, <italic>CCND1</italic>, <italic>MAP2K2</italic>, <italic>MAPK3</italic>, <italic>TP53</italic>, <italic>THBS1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa04540</td>
<td align="left" valign="top">Gap junction</td>
<td align="center" valign="top">1.28E-03</td>
<td align="center" valign="top">13</td>
<td align="left" valign="top"><italic>ADCY3</italic>, <italic>EGFR</italic>, <italic>GNAI2</italic>, <italic>MAP2K2</italic>, <italic>GNA11</italic>, <italic>LPAR1</italic>, <italic>ITPR3</italic>, <italic>MAPK1</italic>, <italic>ADCY9</italic>, <italic>CSNK1D</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa00980</td>
<td align="left" valign="top">Metabolism of xenobiotics by cytochrome P450</td>
<td align="center" valign="top">2.44E-03</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top"><italic>GSTM1</italic>, <italic>AKR1C3</italic>, <italic>GSTM2</italic>, <italic>AKR1C2</italic>, <italic>CYP1B1</italic>, <italic>ADH5</italic>, <italic>GSTT1</italic>, <italic>EPHX1</italic>, <italic>AKR1C1</italic>, <italic>ALDH3B1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa05216</td>
<td align="left" valign="top">Thyroid cancer</td>
<td align="center" valign="top">2.48E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;7</td>
<td align="left" valign="top"><italic>MAPK1</italic>, <italic>CCND1</italic>, <italic>MAP2K2</italic>, <italic>RXRA</italic>, <italic>MAPK3</italic>, <italic>TP53</italic>, <italic>TCF7L1</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa05212</td>
<td align="left" valign="top">Pancreatic cancer</td>
<td align="center" valign="top">2.57E-03</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>EGFR</italic>, <italic>VEGFB</italic>, <italic>MAPK1</italic>, <italic>VEGFC</italic>, <italic>CCND1</italic>, <italic>RELA</italic>, <italic>MAPK3</italic>, <italic>TP53</italic>, <italic>SMAD3</italic>, <italic>SMAD2</italic></td>
</tr>
<tr>
<td/>
<td align="center" valign="top">hsa05220</td>
<td align="left" valign="top">Chronic myeloid leukemia</td>
<td align="center" valign="top">3.49E-03</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>MAPK1</italic>, <italic>CTBP1</italic>, <italic>CCND1</italic>, <italic>MAP2K2</italic>, <italic>RELA</italic>, <italic>MAPK3</italic>, <italic>TP53</italic>, <italic>SMAD3</italic>, <italic>BCL2L1</italic>, <italic>ABL1</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-mmr-16-05-7617"><p>DEGs, differentially expressed genes; GO, Gene Ontology; Up, upregulated; Down, downregulated.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-mmr-16-05-7617" position="float">
<label>Table II.</label>
<caption><p>Differentially expressed genes with a connectivity degree of &#x2265;10 in the protein-protein interaction network.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">ID</th>
<th align="center" valign="bottom">Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">CDK1</td>
<td align="center" valign="top">29</td>
</tr>
<tr>
<td align="left" valign="top">MAD2L1</td>
<td align="center" valign="top">23</td>
</tr>
<tr>
<td align="left" valign="top">NDC80</td>
<td align="center" valign="top">20</td>
</tr>
<tr>
<td align="left" valign="top">NCAPG</td>
<td align="center" valign="top">20</td>
</tr>
<tr>
<td align="left" valign="top">BUB1</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top">CENPF</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top">KIF11</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="left" valign="top">DLGAP5</td>
<td align="center" valign="top">17</td>
</tr>
<tr>
<td align="left" valign="top">CREBBP</td>
<td align="center" valign="top">17</td>
</tr>
<tr>
<td align="left" valign="top">BIRC5</td>
<td align="center" valign="top">17</td>
</tr>
<tr>
<td align="left" valign="top">RFC4</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">RRM2</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">TP53</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">AURKA</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">SF3A2</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">ASPM</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">SNRPG</td>
<td align="center" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top">MAPK1</td>
<td align="center" valign="top">12</td>
</tr>
<tr>
<td align="left" valign="top">HMMR</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">NUP107</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">CDKN3</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">PPP1CC</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">SRSF1</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">RACGAP1</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">NUP160</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">ZWINT</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">SRSF3</td>
<td align="center" valign="top">10</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tIII-mmr-16-05-7617" position="float">
<label>Table III.</label>
<caption><p>GO terms and pathways enriched for the DEGs in the most significant module.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom" colspan="5">A, Top 10 GO terms enriched for the DEGs in the most significant module</th>
</tr>
<tr>
<th align="center" valign="bottom" colspan="5"><hr/></th>
</tr>
<tr>
<th align="left" valign="bottom">Term</th>
<th align="center" valign="bottom">Description</th>
<th align="center" valign="bottom">P-value</th>
<th align="center" valign="bottom">n</th>
<th align="center" valign="bottom">Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">GO:0000280</td>
<td align="left" valign="top">Nuclear division</td>
<td align="center" valign="top">9.92E-16</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0007067</td>
<td align="left" valign="top">Mitosis</td>
<td align="center" valign="top">9.92E-16</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0000087</td>
<td align="left" valign="top">M phase of mitotic cell cycle</td>
<td align="center" valign="top">1.19E-15</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0048285</td>
<td align="left" valign="top">Organelle fission</td>
<td align="center" valign="top">1.49E-15</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0000278</td>
<td align="left" valign="top">Mitotic cell cycle</td>
<td align="center" valign="top">1.86E-15</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0022402</td>
<td align="left" valign="top">Cell cycle process</td>
<td align="center" valign="top">2.11E-15</td>
<td align="center" valign="top">13</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>DLGAP5</italic>, <italic>CENPF</italic>, <italic>AURKA, NDC80</italic>, <italic>BIRC5</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0022403</td>
<td align="left" valign="top">Cell cycle phase</td>
<td align="center" valign="top">6.44E-15</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic>, <italic>ASPM</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0000279</td>
<td align="left" valign="top">M phase</td>
<td align="center" valign="top">5.81E-14</td>
<td align="center" valign="top">11</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>DLGAP5, BUB1</italic>, <italic>CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0007049</td>
<td align="left" valign="top">Cell cycle</td>
<td align="center" valign="top">9.57E-14</td>
<td align="center" valign="top">13</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>KIF11</italic>, <italic>DLGAP5</italic>, <italic>CENPF</italic>, <italic>AURKA, NDC80</italic>, <italic>BIRC5</italic>, <italic>MAD2L1</italic>, <italic>NCAPG</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td align="left" valign="top">GO:0051301</td>
<td align="left" valign="top">Cell division</td>
<td align="center" valign="top">1.80E-12</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>KIF11</italic>, <italic>NCAPG</italic>, <italic>BUB1, CENPF</italic>, <italic>BIRC5</italic>, <italic>NDC80</italic>, <italic>RACGAP1</italic>, <italic>ASPM</italic></td>
</tr>
<tr>
<td align="center" valign="top" colspan="5"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="5">B, Pathways enriched for the DEGs in the most significant module</td>
</tr>
<tr>
<td align="center" valign="top" colspan="5"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Term</td>
<td align="center" valign="top">Description</td>
<td align="center" valign="top">P-value</td>
<td align="center" valign="top">n</td>
<td align="center" valign="top">Genes</td>
</tr>
<tr>
<td align="center" valign="top" colspan="5"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">hsa04114</td>
<td align="left" valign="top">Oocyte meiosis</td>
<td align="center" valign="top">1.88E-04</td>
<td align="center" valign="top">&#x00A0;&#x00A0;4</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>BUB1</italic>, <italic>AURKA</italic></td>
</tr>
<tr>
<td align="left" valign="top">hsa04914</td>
<td align="left" valign="top">Progesterone-mediated oocyte maturation</td>
<td align="center" valign="top">4.06E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;3</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>BUB1</italic></td>
</tr>
<tr>
<td align="left" valign="top">hsa04110</td>
<td align="left" valign="top">Cell cycle</td>
<td align="center" valign="top">8.43E-03</td>
<td align="center" valign="top">&#x00A0;&#x00A0;3</td>
<td align="left" valign="top"><italic>CDK1</italic>, <italic>MAD2L1</italic>, <italic>BUB1</italic></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn2-mmr-16-05-7617"><p>DEGs, differentially expressed genes; GO, Gene Ontology.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>